Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.48 |
| ▸ | FOS | P01100 | 8/20 | 0.44 |
| ▸ | JUN | P05412 | 8/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 8/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 8/20 | 0.44 |
| ▸ | RELA | Q04206 | 8/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | XPO1 | O14980 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996018 | 0.93 | NPSR1 (0.53) | FLT3FOSJUNNFKB1NFKB2 | |
| SCHEMBL4786431 | 0.91 | NPSR1 (0.53) | FLT3FOSJUNNFKB1NFKB2 | |
| SCHEMBL4787812 | 0.91 | FLT3 (0.47) | FLT3FOSJUNNFKB1NFKB2 | |
| SCHEMBL4785941 | 0.91 | FLT3 (0.48) | FLT3FOSJUNNFKB1NFKB2 | |
| SCHEMBL8379706 | 0.89 | JUN (0.52) | FLT3FOSJUNNFKB1NFKB2 | |
| SCHEMBL4784974 | 0.89 | FLT3 (0.46) | FLT3FOSJUNNFKB1NFKB2 | |
| SCHEMBL8378162 | 0.88 | FOS (0.52) | FLT3FOSJUNNFKB1NFKB2 | |
| SCHEMBL4785196 | 0.86 | FLT3 (0.49) | FLT3FOSJUNNFKB1NFKB2 | |
| SCHEMBL4787489 | 0.86 | FLT3 (0.45) | FLT3FOSJUNNFKB1NFKB2 | |
| SCHEMBL4788369 | 0.85 | FOS (0.44) | FLT3FOSJUNNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008110891-A2 | NEW HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED, (IN) | 2008-09-18 | — | — | WO | claimed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | claimed |
| WO-2008110891-A2 | NEW HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED, (IN) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221103-A1 | New heterocyclic compounds | LOXL4, CXCR4, LTC4S | FLT3 1941/4885FOS 1166/4885JUN 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.